By Adria Calatayud
AstraZeneca reached a deal valued at up to $2.02 billion to license an experimental therapy for a disorder affecting cholesterol and related cardiovascular diseases from CSPC Pharmaceutical Group.
The U.K. pharmaceutical giant said Monday that CSPC will receive an upfront payment of $100 million and could receive up to $1.92 billion for further development and commercialization milestones plus royalties.
The agreement gives AstraZeneca access to a molecule discovered by CSPC, known as YS2302018, with the aim of developing it as a therapy with potential in a range of cardiovascular diseases, it said.
The molecule that AstraZeneca is licensing has been shown to prevent the formation of a protein that plays a key role in the transport of cholesterol in the blood stream, but has yet to be assessed in clinical trials.
The therapy candidate adds to AstraZeneca's cardiovascular pipeline and could help patients with dyslipidemia--a disorder affecting cholesterol--and related cardiometabolic diseases, said Sharon Barr, AstraZeneca executive vice president and head of bioPharmceuticals research and development.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
October 07, 2024 05:31 ET (09:31 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。